Denali Therapeutics (NASDAQ:DNLI) had its "buy" rating reaffirmed by analysts at BTIG Research. They now have a $32.00 price target on the stock.
Denali Therapeutics (NASDAQ:DNLI) had its "outperform" rating reaffirmed by analysts at Wedbush.
Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement
Denali Therapeutics (NASDAQ:DNLI) was given a new $37.00 price target on by analysts at Stifel Nicolaus.
Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights [Yahoo! Finance]